Abstract
Wilson’s disease, or hepatolenticular degeneration, is an inherited disorder of copper metabolism, characterized by decreased biliary excretion of the metal. Copper accumulation and deposition in a variety of organ systems results in progressive tissue injury and leads inexorably to death unless appropriate therapy is initiated. Kinnear Wilson first described the familial syndrome of “progressive lenticular degeneration associated with cirrhosis of the liver” in 1912. This chapter will attempt to review the current understanding of Wilson’s disease, highlighting some of he recent advances and controversies in the pathogenesis and management of this disorder.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bloomer LC, Lee GR (1978) Normal hepatic copper metabolism. In: Powell LW (ed) Metals and liver. Marcel Dekker, New York, pp 179–239
Saltzman BE, Gross SB, Yeager DW et al. (1990) Total body burdens and tissue concentrations of lead, cadmium, copper, zinc, and ash in 55 human cadavers. Environment Res 52:126–145
Turnlund JR, Keyes WR, Anderson HL et al. (1989) Copper absorption and retention in young men at three levels of dietary copper by use of the stable isotope 65Cu. Am J Clin Nutr 49: 870–878
Lipsky MA, Gollan JL (1987) Treatment of Wilson’s disease: In d- penicillamine we trust - What about zinc? Hepatology 7:593–595
Sternlieb I, Morell AG, Tucker WD et al. (1961) The incorporation of copper into ceruloplasmin in vivo: studies with copper64 and copper67. J Clin Invest 40:1834–1840
Sternlieb I, Scheinberg IH (1979) The role of radiocopper in the diagnosis of Wilson’s disease. Gastroenterology 77:138–142
Cousins RJ (1985) Absorption, transport, and hepatic metabolism of copper and zinc: special reference to metallothionein and ceruloplasmin. Physiol Rev 65:238–309
Frommer DJ (1976) Direct measurement of serum non-ceruloplasmin copper in liver disease. Clin Chim Acta 68:303–307
Neumann PZ, Sass-Kortsak A (1967) The state of copper in human serum. Evidence for an amino-acid bound fraction. J Clin Invest 46:646–658
Barrow L, Tanner MS (1988) Copper distribution among serum proteins in pediatric liver disorders and malignancies. Eur J Clin Invest 18:555–560
German JL, Bearn AG (1961) Effects of estrogens on copper metabolism in Wilson’s disease. J Clin Invest 40:445–453
Van Berge Henegouwen GP, Tangedahl TN, Hoffmann AF et al. (1977) Biliary secretion of copper in healthy man: quantitation by an intestinal perfusion technique. Gastroenterology 72:1228–1231
Sternlieb I, Van den Hamer CJA, Morell AG et al. (1973) Lysosomal defects of hepatic copper excretion in Wilson’s disease. Gastroenterology 64:99–105
Strickland GT, Beckner WM, Leu ML (1972) Absorption of copper in homozygotes and heterozygotes for Wilson’s disease and controls: isotope tracer studies with 67Cu and 64Cu. Clin Sci 43:617–625
Frydman M (1990) Genetic aspects of Wilson’s disease. J Gastroenterol Hepatol 5:483–490
Frydman M, Bonne-Tamir B, Farrer LA et al. (1985) Assignment of the gene for Wilson’s disease to chromosome 13: linkage to the esterase D locus. Proc Natl Acad Sci USA 82:1819–1821
Figus A, Lampis R, Devoto M et al. (1989) Carrier detection and early diagnosis of Wilson’s disease by restriction fragment length polymorphism analysis. J Med Genet 26:78–82
Bowcock AM, Farrer LA, Hebert JM et al. (1988) Eight closely linked loci place the Wilson disease locus within 13ql4-q21. Am J Human Genet 43:664–674
Esquivel CO, Marino IR, Fioravanti V et al. (1988) Liver transplantation for metabolic disease of the liver. Gastroenterol Clin North Am 17:167–175
Frommer DJ (1974) Defective biliary excretion of copper in Wilson’s disease. Gut 15:125–129
Sternlieb I (1990) Perspectives on Wilson’s disease. Hepatology 12:1234–1239
Evans J, Newman SP, Sherlock S (1980) Observations on copper-associated protein in childhood liver disease. Gut 21:970–976
Iyengar V, Brewer GJ, Dick RD et al. (1988) Studies of cholecystokinin- stimulated biliary secretions reveal a high molecular weight copper-binding substance in normal subjects that is absent in patients with Wilson’s disease. J Lab Clin Med 111:267–274
Vierling JM, Shrager R, Rumble WF et al. (1978) Incorporation of radiocopper into ceruloplasmin in normal subjects and in patients with primary biliary cirrhosis and Wilson’s disease. Gastroenterology 74:652–660
Czaja MJ, Weiner FR, Schwarzenberg SJ et al. (1987) Molecular studies of ceruloplasmin deficiency in Wilson’s disease. J Clin Invest 80:1200–1204
Barrow L, Tanner MS, Critchley DR (1989) Expression of the caeruloplasmin gene in the adult and neonatal rat liver. Clin Sci 77:259–263
Epstein O, Sherlock S (1981) Is Wilson’s disease caused by a controller gene mutation resulting in perpetuation of the fetal mode of copper metabolism? Lancet I:303–305
Cartwright GE, Lee GR (1974) The pathogenesis and evolution of Wilson’s disease. Epatologia 20:51–56
Danks DM, Metz G, Sewell R et al. (1990) Wilson’s disease in adults with cirrhosis but no neurological abnormalities. Br Med J 301:331–332
Sternlieb I, Scheinberg IH (1985) Wilson’s disease. In: Wright R, Alberti KGM, Karran S et al. (eds) Liver and biliary disease. Bailliere Tindall, London, pp 949–961
Strickland GT, Frommer D, Leu ML et al. (1973) Wilson’s disease in the United Kingdom and Taiwan. Q J Med 42:619–638
Walshe JM (1989) Wilson’s disease presenting with features of hepatic dysfunction: a clinical analysis of eighty-seven patients. Q J Med 70:253–263
Sternlieb I (1975) The development of cirrhosis in Wilson’s disease. Clin Gastroenterol 4:367–379
Scott J, Gollan JL, Samourian S et al. (1978) Wilson’s disease presenting as chronic active hepatitis. Gastroenterology 74:645–651
Sternlieb I, Scheinberg IH (1972) Chronic hepatitis as a first manifestation of Wilson’s disease. Ann Intern Med 76:59–64
Davies SE, Williams R, Portmann B (1989) Hepatic morphology and histochemistry of Wilson’s disease presenting as fulminant hepatic failure: a study of 11 cases. Histopathology 15:385–394
McCullough AJ, Fleming CR, Thistle JL et al. (1983) Diagnosis of Wilson’s disease presenting as fulminant hepatic failure. Gastroenterology 84:161–167
Berman DH, Leventhal RI, Gavaler JS et al. (1989) Rapid clinical identification of fulminant Wilson’s disease from other causes of fulminant hepatic failure using readily available laboratory tests (abstr). Hepatology 10:574
Frommer D, Morris J, Sherlock S et al. (1977) Kayser-Fleischer-like rings in patients without Wilson’s disease. Gastroenterology 72:1331–1335
Nazer H, Ede RJ, Mowat AP et al. (1986) Wilson’s disease: clinical presentation and use of prognostic index. Gut 27:1377–1381
Rosenfeld N, Grand RJ, Watkins JB et al. (1978) Cholelithiasis and Wilson’s disease. Pediatrics 92:210–213
Weizman Z, Picard E, Barki Y et al. (1988) Case report: Wilson’s disease associated with pancreatitis. J Pediatr Gastroenterol Nutr 7:931–933
Leu ML, Strickland GT, Yeh SJ (1971) Tissue copper, zinc, and manganese levels in Wilson’s disease: studies with the use of neutron activation analysis. J Lab Clin Med 77:438–444
Dreiling DA, Grateron H (1983) Studies in pancreatic secretion. VIII. Pancreatic function in patients with Wilson’s disease. J Mt Sinai Hosp 50:335–337
Lankisch PG, Kaboth U, Koop H (1978) Pankreasbeteiligung bei Morbus Wilson? Klin Wochenschr 56:969–971
Person J, Anderson DS, Brower RA (1987) Spontaneous bacterial peritonitis in Wilson’s disease. Am J Gastroenterol 82:66–68
Marsden CD (1987) Wilson’s disease (editorial). Q J Med 65:959–966
Lang C, Muller D, Claus D et al. (1990) Neuropsychological findings in treated Wilson’s disease. Acta Neurol Scand 81:75–81
Dening TR, Berrios GE, Walshe JM (1988) Wilson’s disease and epilepsy. Brain 111:1139–1155
Westmoreland BF, Goldstein NP, Klass DW (1974) Wilson’s disease. Electroencephalographic and evoked potential studies. Mayo Clin Proc 49:401–404
Frankel JP, Hughes A, Lees AJ et al. (1989) Use of apomorphine to test for dopamine responsiveness in Wilson’s disease (letter). Lancet II:801–802
Goldstein NP, Ewert JC, Randall RV et al. (1968) Psychiatric aspects of Wilson’s disease (hepatolenticular degeneration): results of psychometric tests during long term therapy. Am J Psychiatr 124:1555–1561
Deiss A, Lee GR, Cartwright GE (1970) Hemolytic anemia in Wilson’s disease. Ann Intern Med 73:413–418
Owen CA, Goldstein NP, Bowie EJ (1976) Platelet function and coagulation in patients with Wilson’s disease. Arch Intern Med 136:148–152
Wiebers DO, Hollenhorst RW, Goldstein NP (1977) The ophthalmologic manifestations of Wilson’s disease. Mayo Clin Proc 52:409–416
Lobner A, Lobner J, Bachmann H et al. (1986) The Kayser-Fleischer ring during long-term treatment in Wilson’s disease (hepatolenticular degeneration): a follow-up study. Graefes Arch Clin Exp Ophthalmol 224:152–155
Cairns JE, Williams HP, Walshe JM (1969) “Sunflower cataract” in Wilson’s disease. Br J Med 3:95–96
Leu ML, Strickland GT, Gutman RA (1970) Renal function in Wilson’s disease: response to penicillamine therapy. Am J Med Sci 260:381–398
Fulop M, Sternlieb I, Scheinberg IH (1968) Defective urinary acidification in Wilson’s disease. Ann Intern Med 68:770–777
Asatoor AM, Milne MD, Walshe JM (1976) Urinary excretion of peptides and of hydroxyproline in Wilson’s disease. Clin Sci Mol Med 51:369–378
Wiebers DO, Wilson DM, McLeod RA et al. (1979) Renal stones in Wilson’s disease. Am J Med 67:249–254
Steen VD, Blair S, Medsger TA (1986) The toxicity of D-penicillamine in systemic sclerosis. Ann Intern Med 104:699–705
Kuan P (1987) Cardiac Wilson’s disease. Chest 91:579–583
Factor SM, Cho S, Sternlieb I et al. (1982) The cardiomyopathy of Wilson’s disease: myocardial alterations in nine cases. Virchows Arch 397:301–311
Mindelzun R, Elkin M, Scheinberg IH et al. (1970) Skeletal changes in Wilson’s disease: a radiological study. Radiology 94:127–132
Menerey KA, Eider W, Brewer GJ et al. (1988) The arthropathy of Wilson’s disease: clinical and pathologic features. J Rheumatol 15:331–337
Lugassy G, Michaeli J, Oren R (1988) Wilson’s disease presenting as isolated arthritis of the hip (letter). Arthritis Rheum 31:573–575
Johansen K, Gregersen G (1972) Glucose intolerance in Wilson’s disease. Arch Intern Med 129:587–590
Carpenter TO, Carnes DL, Anast CS (1983) Hypoparathyroidism in Wilson’s disease. N Engl J Med 309:873–877
Kaushansky A, Frydman M, Kaufman H et al. (1987) Endocrine studies of the ovulatory disturbances in Wilson’s disease (hepatolenticular degeneration). Fertil Steril 47:270–273
Sternlieb I, Scheinberg IH (1968) Prevention of Wilson’s disease in asymptomatic patients. N Engl J Med 278:352–359
Sternlieb I (1968) Mitochondrial and fatty changes in hepatocytes of patients with Wilson’s disease. Gastroenterology 55:354–367
Stromeyer FW, Ishak HG (1980) Histology of the liver in Wilson’s disease. A study of 34 cases. Am J Clin Pathol 73:12–24
Geubel AP, Gregoire V, Rahier J et al. (1988) Hypoceruloplasminemia and ultrastructural changes resembling Wilson’s disease in non-alcoholic liver steatosis: a clinical and pathological study of five cases. Liver 8:299–306
Wilkinson ML, Portmann B, Williams R (1983) Wilson’s disease and hepatocellular carcinoma: possible protective role of copper. Gut 24:767–771
Horoupian DS, Sternlieb I, Scheinberg IH (1988) Neuropathological findings in penicillamine-treated patients with Wilson’s disease. Clin Neuropathol 7:62–67
Perman JA, Werlin SL, Grand RJ et al. (1979) Laboratory measures of copper metabolism in the differentiation of chronic active hepatitis and Wilson’s disease in children. J Pediatr 94:564–568
LaRusso NF, Summerskill WHJ, McCall JT (1976) Abnormalities of chemical tests for copper metabolism in chronic active liver disease: differentiation from Wilson’s disease. Gastroenterology 70:653–655
Spechler SJ, Koff RS (1980) Wilson’s disease: diagnostic difficulties in the patient with chronic hepatitis and hypoceruloplasminemia. Gastroenterology 78:803–806
Frommer DJ (1981) Urinary copper excretion and hepatic copper concentrations in liver disease. Digestion 21:169–178
Smallwood RA, Williams HA, Rosenoer VM et al. (1968) Liver-copper levels in liver disease: studies using neutron activation analysis. Lancet II:1310–1313
Grimm G, Oder W, Prayer L et al. (1990) Evoked potentials in assessment and follow-up of patients with Wilson’s disease. Lancet 336:963–964
Weisner B, Hartard C, Dieu C (1987) CSF copper concentration: a new parameter for diagnosis and monitoring therapy of Wilson’s disease with cerebral manifestations. J Neurol Sci 79:229–237
Dixon AK, Walshe JM (1984) Computed tomography of the liver in Wilson’s disease. J Comput Assist Tomogr 8:46–49
Lawler GA, Pennock JM, Steiner RE et al. (1983) Nuclear magnetic resonance (NMR) imaging in Wilson’s disease. J Comput Assist Tomogr 7:1–8
Gainey MA, Faerber EN (1985) Disparate hepatic imaging with technetium- 99m sulfur colloid and disofenin in Wilson’s disease. J Nucl Med 26:368–372
Williams JB, Walshe JM (1981) Wilson’s disease: an analysis of the computerized tomographic appearances found in 60 patients and the changes in response to treatment with chelating agents. Brain 104:735–752
Rothfus WE, Hirsch WL, Malatack JJ et al. (1988) Case report: improvement of cerebral CT abnormalities following liver transplantation in a patient with Wilson’s disease. J Comput Assist Tomogr 12:138–140
Prayer L, Wimberger D, Kramer J et al. (1990) Cranial MRI in Wilson’s disease. Neuroradiology 32:211–214
Sternlieb I, Scheinberg IH (1964) Penicillamine therapy in hepatolenticular degeneration. JAMA 189:748–754
Gibbs K, Walshe JM (1990) Liver copper concentration in Wilson’s disease: effect of treatment with “anti-copper” agents. J Gastroenterol Hepatol 5:420–424
Scheinberg IH, Sternlieb I, Schilsky M et al. (1987) Penicillamine may detoxify copper in Wilson’s disease (letter). Lancet II:95
Brewer GJ, Terry CA, Aisen AM et al. (1987) Worsening of neurologic syndrome in patients with Wilson’s disease with initial penicillamine therapy. Arch Neurol 44:490–493
Walshe JM (1982) Treatment of Wilson’s disease with trientine (triethylene tetramine) dihydrochloride. Lancet I:643–647
Scheinberg IH, Jaffe ME, Sternlieb I (1987) The use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson’s disease. N Engl J Med 317:209–213
Epstein O, Sherlock S (1980) Triethylene tetramine dihydrochloride toxicity in primary biliary cirrhosis. Gastroenterology 78:1442–1445
Brewer GJ, Hill GM, Prasad AS et al. (1983) Oral zinc therapy for Wilson’s disease. Ann Intern Med 99:314–320
Schilsky ML, Blank RR, Czaja MJ et al. (1989) Hepatocellular copper toxicity and its attenuation by zinc. J Clin Invest 84:1562–1568
Stremmel W, Strohmeyer G (1988) Oral zinc therapy is not always effective for treatment of Wilson’s disease (abstr). Hepatology 8:1335
Scheinberg IH, Sternlieb I (1988) The efficacy of oral zinc therapy as an alternative to penicillamine for Wilson’s disease (letter). N Engl J Med 318:323
Walshe JM (1986) Tetrathiomolybdate (MoS4) as an anti-copper agent in man. In: Scheinberg IH, Walshe JM (eds) Orphan diseases and orphan drugs. Manchester University Press, Manchester, pp 76–85
Harper PL, Walshe JM (1986) Reversible pancytopenia secondary to treatment with tetrathiomolybdate. Br J Haematol 64:851–853
Walshe JM, Dixon AK (1986) Dangers of non-compliance in Wilson’s disease. Lancet I:845–847
Scheinberg IH, Sternlieb I (1975) Pregnancy in penicillamine-treated patients with Wilson’s disease. N Engl J Med 293:1300–1302
Walshe JM (1977) Pregnancy in Wilson’s disease. Q J Med 46:73–83
Walshe JM (1986) The management of pregnancy in Wilson’s disease treated with trientine. O J Med 58:81–87
Sternlieb I (1988) Wilson’s disease: transplantation when all else has failed. Hepatology 8:975–976
Poison RJ, Rolles K, Calne RY et al. (1987) Reversal of severe neurologic manifestations of Wilson’s disease following orthotopic liver transplantation. Q J Med 64:685–691
Rakela J, Kurtz SB, McCarthy JT et al. (1988) Postdilution hemofiltration in the management of acute hepatic failure: a pilot study. Mayo Clin Proc 63:113–118
Cartwright GE (1978) Diagnosis of treatable Wilson’s disease. N Engl J Med 298:1347–1350
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Zucker, S.D., Gollan, J.L. (1992). Wilson’s Disease: Pathophysiology and Therapy. In: Prieto, J., Rodés, J., Shafritz, D.A. (eds) Hepatobiliary Diseases. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76802-6_23
Download citation
DOI: https://doi.org/10.1007/978-3-642-76802-6_23
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-76804-0
Online ISBN: 978-3-642-76802-6
eBook Packages: Springer Book Archive